WhatsApp

Chemotherapy Before Surgery in Pancreatic Cancer: Two Common Options Show Similar Survival

You are here >> Home > Latest Updates > Pancreas Cancer Updates > Chemotherapy Before…

Chemotherapy Before Surgery in Pancreatic Cancer - Two Common Options Show Similar Survival

Patients with pancreatic cancer often receive chemotherapy before surgery. This is called neoadjuvant or induction treatment. Doctors usually choose between two drug combinations: FOLFIRINOX or gemcitabine with nab-paclitaxel. Both are standard treatments, but it has not been clear which one helps patients live longer after surgery.

A large international study looked at this question. Researchers studied 935 patients with pancreatic cancer who received either FOLFIRINOX or gemcitabine-nab-paclitaxel before surgery. These patients came from 16 hospitals in 8 different countries.

The results showed that survival after surgery was similar for both groups. This means that, on average, patients who had FOLFIRINOX did not live longer than those who had gemcitabine-nab-paclitaxel.

The study also found one important detail. Patients whose blood test (CA19-9) was normal or only slightly raised seemed to do better with FOLFIRINOX. This suggests that the best choice of treatment may depend on each patient’s individual test results.

For patients, this means that both chemotherapy options remain valid before surgery. Doctors may choose the treatment based on how well a patient can tolerate side effects, blood test results, and personal health factors.

This study gives patients and doctors more confidence that both treatment paths are reasonable, and that personal factors should guide the decision.

Rate this post
Dr. Harsh J Shah